137 related articles for article (PubMed ID: 33485700)
41. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
42. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.
Ho GY; Burk RD; Klein S; Kadish AS; Chang CJ; Palan P; Basu J; Tachezy R; Lewis R; Romney S
J Natl Cancer Inst; 1995 Sep; 87(18):1365-71. PubMed ID: 7658497
[TBL] [Abstract][Full Text] [Related]
43. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
44. Human papillomavirus: often harmless but in some cases carcinogenic.
Prescrire Int; 2007 Jun; 16(89):115-9. PubMed ID: 17585425
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and type distribution of human papillomavirus in women with cervical lesions in Liaoning Province, China.
Liu X; Zhang S; Ruan Q; Ji Y; Ma L; Zhang Y
Int J Gynecol Cancer; 2010 Jan; 20(1):147-53. PubMed ID: 20130516
[TBL] [Abstract][Full Text] [Related]
46. The Relationships Between Social Media and Human Papillomavirus Awareness and Knowledge: Cross-sectional Study.
Jo S; Pituch KA; Howe N
JMIR Public Health Surveill; 2022 Sep; 8(9):e37274. PubMed ID: 36125858
[TBL] [Abstract][Full Text] [Related]
47. The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?
Cox JT
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s5-s13. PubMed ID: 16520683
[TBL] [Abstract][Full Text] [Related]
48. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
[TBL] [Abstract][Full Text] [Related]
49. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study.
Prétet JL; Jacquard AC; Saunier M; Clavel C; Dachez R; Gondry J; Pradat P; Soubeyrand B; Leocmach Y; Mougin C; Riethmuller D;
Gynecol Oncol; 2008 Aug; 110(2):179-84. PubMed ID: 18514800
[TBL] [Abstract][Full Text] [Related]
50. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review.
Raposo A; Tani C; Costa J; Mosca M
Acta Reumatol Port; 2016; 41(3):184-190. PubMed ID: 27682966
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study.
Tam LS; Chan PK; Ho SC; Yu MY; Yim SF; Cheung TH; Wong MC; Cheung JL; Li EK
Arthritis Care Res (Hoboken); 2011 Feb; 63(2):269-76. PubMed ID: 20890985
[TBL] [Abstract][Full Text] [Related]
52. The vaginal microbiome: A complex milieu affecting risk of human papillomavirus persistence and cervical cancer.
Alimena S; Davis J; Fichorova RN; Feldman S
Curr Probl Cancer; 2022 Aug; 46(4):100877. PubMed ID: 35709613
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus.
Lyrio LD; Grassi MF; Santana IU; Olavarria VG; Gomes Ado N; CostaPinto L; Oliveira RP; Aquino Rde C; Santiago MB
Rheumatol Int; 2013 Feb; 33(2):335-40. PubMed ID: 22451033
[TBL] [Abstract][Full Text] [Related]
54. Conceptual, statistical and clinical interpretation of results from a systematic review and meta-analysis of prevalence of cervical HPV infection in women with SLE.
Jayaraj R; Kumarasamy C
Autoimmun Rev; 2019 Apr; 18(4):433-434. PubMed ID: 30763632
[No Abstract] [Full Text] [Related]
55. Prevalence and genotype distribution of human papillomavirus among women with cervical lesions in Shenzhen city, China.
Mai Q; Yang X; Cheng H; Wu G; Wu Z
Hum Vaccin Immunother; 2021 Apr; 17(4):965-971. PubMed ID: 32961080
[TBL] [Abstract][Full Text] [Related]
56. Implementation strategies to increase human papillomavirus vaccination uptake for adolescent girls in sub-Saharan Africa: A scoping review protocol.
Lubeya MK; Mwanahamuntu M; Chibwesha C; Mukosha M; Wamunyima MM; Kawonga M
PLoS One; 2022; 17(8):e0267617. PubMed ID: 36006961
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
Onuki M; Yamamoto K; Yahata H; Kanao H; Yokota H; Kato H; Shimamoto K; Takehara K; Kamiura S; Tsuda N; Takei Y; Shigeta S; Matsumura N; Yoshida H; Motohara T; Watari H; Nakamura K; Ueda A; Tasaka N; Ishikawa M; Hirashima Y; Kudaka W; Taguchi A; Iwata T; Takahashi F; Kukimoto I; Yoshikawa H; Yaegashi N; Matsumoto K;
Cancer Sci; 2022 Apr; 113(4):1428-1434. PubMed ID: 35043515
[TBL] [Abstract][Full Text] [Related]
58. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
59. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature.
Zard E; Arnaud L; Mathian A; Chakhtoura Z; Hie M; Touraine P; Heard I; Amoura Z
Autoimmun Rev; 2014 Jul; 13(7):730-5. PubMed ID: 24657969
[TBL] [Abstract][Full Text] [Related]
60. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
